Abstract
We report results of our prospective study - administration of Nebilet in 30 patients in perioperative period. Aim of this study is to estimate the protective effect of Nebilet for perioperative cardiac complications (nonfatal myocardial infarction and cardiac death) in patients which underwent recostructive vascular surgery. Patients were administrated Nebilet (2.5 to 7.5 mg/per day, according to arterial pressure and heart rates) 20 days before operation and 2 months after surgery. In early postoperative period we performed the control examinations: troponin T (1, 3, 7 days), ECG (1 day), echocardiography (1-2 day) and 2 months after operation (ECG and echocardiography). During whole follow up period we controlled in patients arterial pressure and heart rates.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use*
-
Aged
-
Aged, 80 and over
-
Benzopyrans / therapeutic use*
-
Death, Sudden, Cardiac / etiology
-
Death, Sudden, Cardiac / prevention & control
-
Ethanolamines / therapeutic use*
-
Female
-
Follow-Up Studies
-
Humans
-
Intraoperative Complications / etiology
-
Intraoperative Complications / prevention & control*
-
Male
-
Middle Aged
-
Myocardial Infarction / etiology
-
Myocardial Infarction / prevention & control
-
Nebivolol
-
Peripheral Vascular Diseases / surgery*
-
Platelet Aggregation Inhibitors
-
Prospective Studies
-
Treatment Outcome
-
Vascular Surgical Procedures / adverse effects*
Substances
-
Adrenergic beta-Antagonists
-
Benzopyrans
-
Ethanolamines
-
Platelet Aggregation Inhibitors
-
Nebivolol